Abstract
There is increasing evidence of the potential therapeutic utility of glutamate receptor antagonists in the treatment of several neurodegenerative disorders, including stroke and epilepsy. In the last few years noncompetitive AMPA receptor antagonists have received considerable attention due to their therapeutic potentiality. The discovery of GYKI 52466, the prototype of noncompetitive AMPA receptor antagonists endowed with anticonvulsant and neuroprotective properties, induced growing interest on 2,3-benzodiazepine derivatives. This review covers the chemistry and pharmacology of this important class of AMPA receptor antagonists.
Keywords: 2,3-Benzodiazepines, AMPA Receptor, glutamate receptor antagonists, neurodegenerative disorders, Stroke, Epilepsy, Anticonvulsant, Neuroprotective
Mini-Reviews in Medicinal Chemistry
Title: synthesis and Structure-Activity Relationships of 2,3-Benzodiazepines as AMPA Receptor Antagonists
Volume: 1 Issue: 3
Author(s): M. Zappala, S. Grasso, N. Micale, S. Polimeni and C. De Micheli
Affiliation:
Keywords: 2,3-Benzodiazepines, AMPA Receptor, glutamate receptor antagonists, neurodegenerative disorders, Stroke, Epilepsy, Anticonvulsant, Neuroprotective
Abstract: There is increasing evidence of the potential therapeutic utility of glutamate receptor antagonists in the treatment of several neurodegenerative disorders, including stroke and epilepsy. In the last few years noncompetitive AMPA receptor antagonists have received considerable attention due to their therapeutic potentiality. The discovery of GYKI 52466, the prototype of noncompetitive AMPA receptor antagonists endowed with anticonvulsant and neuroprotective properties, induced growing interest on 2,3-benzodiazepine derivatives. This review covers the chemistry and pharmacology of this important class of AMPA receptor antagonists.
Export Options
About this article
Cite this article as:
Zappala M., Grasso S., Micale N., Polimeni S. and De Micheli C., synthesis and Structure-Activity Relationships of 2,3-Benzodiazepines as AMPA Receptor Antagonists, Mini-Reviews in Medicinal Chemistry 2001; 1 (3) . https://dx.doi.org/10.2174/1389557013406783
DOI https://dx.doi.org/10.2174/1389557013406783 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Digitoxin Suppresses Store Operated Calcium Entry by Modulating Phosphorylation and the Pore Region of Orai1
Current Molecular Medicine History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug
Current Topics in Medicinal Chemistry Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Current Pharmaceutical Design Recent Inventions in Powder Technology and Granular Science Incorporating Improved Drug Delivery
Recent Patents on Engineering Antiepileptogenic Effect of Retinoic Acid
Current Neuropharmacology Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Pyrimidine based Semicarbazones: Confirmation of Four Binding Site Pharmacophoric Model Hypothesis for Antiepileptic Activity
Central Nervous System Agents in Medicinal Chemistry Defining Primary and Secondary Progenitor Disorders in the Brain: Proteomic Approaches for Analysis of Neural Progenitor Cells
Current Pharmaceutical Biotechnology PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS
Current Pharmaceutical Design Abnormalities of Cortical Thickness in Pediatric Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis
Current Medical Imaging Complications of Serogroup B Meningococcal Disease in Survivors: A Review
Infectious Disorders - Drug Targets NMDA Receptors and Learning and Memory Processes
Current Drug Targets Early Life Stress in Depressive Patients: Role of Glucocorticoid and Mineralocorticoid Receptors and of Hypothalamic-Pituitary-Adrenal Axis Activity
Current Pharmaceutical Design NPY Signalling Pathway in Bone Homeostasis: Y1 Receptor as a Potential Drug Target
Current Drug Targets Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment
Current Alzheimer Research Development of 1, 3 Benzothiazol-2-yl Hydrazine Derivatives Containing Semicarbazone and Thioamide Pharmacophore as Anticonvulsants
Letters in Drug Design & Discovery In Search of Novel and Therapeutically Significant Melatoninergic Ligands
Recent Patents on CNS Drug Discovery (Discontinued)